Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus insulin glargine in type 2 diabetes patients inadequately controlled on metformin or sulfonylurea
2004-000349-40Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Mar 2005; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-000349-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000349-40.